Drug Profile
Research programme: attention deficit hyperactivity disorder therapeutics - Assertio Therapeutics
Alternative Names: EG-P119Latest Information Update: 28 May 2020
Price :
$50
*
At a glance
- Originator Egalet
- Developer Zyla Life Sciences
- Class
- Mechanism of Action Central nervous system stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Attention-deficit hyperactivity disorder